Castle Biosciences Inc. (CSTL) intrinsic value & 10-year financials
Castle Biosciences Inc. (CSTL) has a Graham intrinsic value of $20.59 per share. At $31.96 on Oct 17, 2026, the stock trades 55% above that value. Over the last 9 fiscal years revenue grew 47.4% a year to $344.2M, with an average return on invested capital of -32.1%.
- Graham intrinsic value
- $20.59
- Share price (Oct 17, 2026)
- $31.96
- Price vs Graham value
- 55% above
- Market cap
- $926.4M
- Revenue (FY2025)
- $344.2M
- Revenue growth (9-yr CAGR)
- 47.4%
- ROIC (10-yr avg)
- -32.1%
- Free cash flow (FY2025)
- $28.3M
CSTL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $344.2M | -$24.2M | -$0.83 | $28.3M | -12.4% | -9.3% |
| FY2024 | $332.1M | $18.2M | $0.62 | $36.5M | 2.6% | 2.2% |
| FY2023 | $219.8M | -$57.5M | -$2.14 | -$19.2M | -30.9% | -22.9% |
| FY2022 | $137.0M | -$67.1M | -$2.58 | -$47.3M | -53.2% | -37.7% |
| FY2021 | $94.1M | -$31.3M | -$1.24 | -$22.5M | -42.6% | -66.0% |
| FY2020 | $62.6M | -$10.3M | -$0.54 | $5.1M | -10.4% | -75.9% |
| FY2019 | $51.9M | $5.3M | -$0.21 | $6.1M | 14.1% | -57.5% |
| FY2018 | $22.8M | -$6.4M | -$5.33 | -$12.6M | -16.8% | 10.5% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CASTLE BIOSCIENCES INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
CASTLE BIOSCIENCES INC has historically struggled to out-earn its cost of capital, averaging just -32.1% ROIC.
CASTLE BIOSCIENCES INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CASTLE BIOSCIENCES INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $20.59 per share.